Polaris Group appointed Chien-Hsing Chang, Vice President of R&D, IMMUNOMEDICS Inc. as Chief Strategy Officer effective June 20, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
72 TWD | +0.98% | +5.26% | -4.76% |
May. 15 | Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA | CI |
May. 14 | Polaris Group Announces Change of the Member of Compensation Committee | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.76% | 1.65B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- 6550 Stock
- News Polaris Group
- Polaris Group Appoints Chien-Hsing Chang as Chief Strategy Officer Effective June 20, 2023